programIg Companion
mobile app
Request a representative
View Full Prescribing Information, including BOXED WARNING, and Patient Information and Instructions for Use.
TERMS AND CONDITIONS
By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
- Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Patient must have private insurance. Offer is not valid for cash paying patients. The value of this co-pay card is limited to a maximum of $12,500 per calendar year or the cost of patient co-pay in a 12-month period, whichever is less.
- This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
- You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
- You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
- The patient must be 2 years of age or older for redemption of co-pay card.
- This co-pay card is not valid where prohibited by law.
- Co-pay card cannot be combined with any other savings, free trial or similar offer for the specified prescription.
- Co-pay card will be accepted only at participating pharmacies.
- If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
- This co-pay card is not health insurance.
- Offer good only in the U.S. and Puerto Rico.
- Co-pay card is limited to 1 per person during this offering period and is not transferable.
- A co-pay card may not be redeemed more than once per 5 days per patient.
- Co-pay card is limited to reimbursement of Pfizer-labeled CUTAQUIG® (Immune Globulin Subcutaneous [Human] - hipp) only.
- No other purchase is necessary.
- No membership fee.
- Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke or amend this offer without notice.
- Offer expires 12/31/2024.
For more information, call 1-866-293-5922, visit CutaquigCoPay.com or write:
CUTAQUIG Co-Pay Program
P.O. Box 6875
Bridgewater, NJ 08807
P.O. Box 6875
Bridgewater, NJ 08807
Reference:
- Cutaquig. Prescribing information. Octapharma USA Inc.; 2021.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
calculator
Interactive calculator to determine a patient's dose, number of sites, and approximate time to complete infusion
Hear from John, a patient with PI, about his path to SCIg therapy and how cutaquig helped him
CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Please see Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.
- Thrombosis may occur with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Full Prescribing Information, Warnings and Precautions (5.2), Patient Counseling Information (17)]
- For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2)]
CUTAQUIG is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of CUTAQUIG, such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Severe hypersensitivity reactions may occur with CUTAQUIG, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the CUTAQUIG infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions.
Thrombosis may occur following treatment with immune globulin products, including CUTAQUIG. For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Falsely elevated blood glucose readings may occur during and after the infusion of CUTAQUIG with some glucometer and test strip systems. When administering CUTAQUIG, measure blood glucose with a glucose-specific method.
Aseptic meningitis syndrome (AMS) can occur with CUTAQUIG. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae.
Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin, especially those containing sucrose. CUTAQUIG does not contain sucrose.
Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. Monitor CUTAQUIG recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after CUTAQUIG infusion.
Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions. If transfusion-related acute lung injury is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum.
CUTAQUIG is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent, and, theoretically, the Creutzfeldt-Jakob disease agent.
The most common adverse reactions (≥5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough.
Drug Interactions
After infusion of CUTAQUIG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield false positive serological test results, with the potential for misleading interpretation.
The passive transfer of antibodies with immunoglobulin administration may interfere with the response to live virus vaccines such as measles, mumps, rubella, and varicella.
Use in Specific Populations
It is not known whether CUTAQUIG can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
No human data are available to indicate the presence or absence of drug-associated risk to lactation and breastfeeding.
Overall safety and efficacy findings in pediatric age group were comparable to those seen in adults. However, infusion site reactions were more commonly observed in adults compared to the pediatric population.
Safety and effectiveness of CUTAQUIG in pediatric patients below the age of 2 have not been established.
Clinical studies of CUTAQUIG did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, to reduce the risk of hyperviscosity and precipitation of cardiac, renal, or hepatic adverse reaction, and of concomitant disease or other drug therapy.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
CUTAQUIG® is a registered trademark of Octapharma AG.
Please click here for Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.